Novo Nordisk


Strong Q1 prompts an improved guidance

05/05/21 -"2021 started on a high as Novo reported robust growth, despite ‘tough comps’, i.e. forward buying-driven Q1 20. Moreover, as management expects this momentum to be maintained, the 2021 outlook has ..."

Pages
73
Language
English
Published on
05/05/21
You may also be interested by these reports :
18/11/26
Leaving aside the mid-term profitability outlook downgrade in 2024, Lundbeck has often exceeded expectations with its operational delivery in the ...

17/11/26
In the last couple of years, most of Roche’s peers – including Novartis, AstraZeneca, Novo Nordisk and Sanofi – have suffered important R&D setbacks, ...

17/11/26
The factors discussed in the justification for DCF valuation have also prompted an upgrade to our NAV valuation. As a result, the target price resets ...

12/11/26
The Q3 results exceeded consensus estimates, backed by the strong showing of Electronics (driven by demand from AI applications) and healthy support ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO